StockNow
Log in
Other

Veru (VERU) announces full enrollment for Phase 2b PLATEAU clinical trial of Enobosarm and Semaglutide (NOVOB DC) combination for high quality weight loss

StockNow breaking-news AI analysis

Veru completed enrollment for its Phase 2b PLATEAU trial on July 27, 2026. The study tests Enobosarm and Semaglutide for high-quality weight loss, with interim data expected in Q1 2027.

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
U.S. Markets

Eli Lilly (LLY) Q2 2026 (USD): Adj. EPS 8.38 (exp. 6.01), Revenue 23bln (exp. 20.7bln)

LLYGeopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday